Soligenix receives $865,000 in non-dilutive funding through new jersey technology business tax certificate transfer program

Princeton, n.j., june 9, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $865,000, net of transaction costs, in non-dilutive financing via the state of new jersey's technology business tax certificate transfer program.
SNGX Ratings Summary
SNGX Quant Ranking